Tumor-associated macrophages are correlated with tamoxifen resistance in the postmenopausal breast cancer patients

Pathology and Oncology Research

Volumn 20, Issue 3, 2014, Pages 619-624

  Xuan, Qi Jia ^a   Wang, Jing Xuan ^a   Nanding, Abiyasi ^a   Wang, Zhi Peng ^a   Liu, Hang ^a   Lian, Xin ^a   Zhang, Qing Yuan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Epidermal growth factor receptor; Obesity; Tamoxifen resistance; Tumor associated macrophages

Indexed keywords

CD163 ANTIGEN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; BREAST TUMOR; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER TISSUE; CELL INFILTRATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MACROPHAGE; MACROPHAGE FUNCTION; MACROPHAGE INFILTRATION; MAJOR CLINICAL STUDY; OBESITY; POSTMENOPAUSE; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; BREAST NEOPLASMS; CANCER STAGING; DRUG EFFECTS; DRUG RESISTANCE; ENZYME IMMUNOASSAY; FOLLOW UP; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MACROPHAGES; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTMENOPAUSE; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, CELL SURFACE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN;

EID: 84904115245     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-013-9740-z     Document Type: Article

References (35)

1. Key TJ, Verkasalo PK, Banks E (2001) Epidemiology of breast cancer. Lancet Oncol 2:133-140 (Pubitemid 33585924)
2. Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9:631-643
3. Gradishar WJ (2004) Tamoxifen-What next? Oncologist 9:378-384
4. Ring A, Dowsett M (2004) Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11:643-658 (Pubitemid 40065543)
5. Beelen K, Zwart W, Linn SC (2012) Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy? Nat Rev Clin Oncol 9:529-541
6. Pollard JW (2008) Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 84:623-630
7. Mantovani A (2005) Cancer: inflammation by remote control. Nature 435:752-753
8. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539-545 (Pubitemid 32173595)
9. Sica A, Schioppa T, Mantovani A et al (2006) Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42:717-727
10. Mantovani A, Sica A, Sozzani S et al (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25:677-686 (Pubitemid 39457982)
11. Lau SK, Chu PG, Weiss LM (2004) CD163 A specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol 122:794-801 (Pubitemid 39434761)
12. Leek RD, Harris AL (2002) Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 7:177-189 (Pubitemid 38420774)
13. Soeda S, Nakamura N, Ozeki T et al (2008) Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol Oncol 109:122-128
14. Konecny GE, Santos L, Winterhoff B et al (2008) HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer 100:89-95
15. García-Becerra R, Santos N, Díaz L et al (2012) Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci 14:108-145
16. McKenna NJ, Lanz RB, O'Malley BW (1999) Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20:321-344 (Pubitemid 30649811)
17. Frasor J, Danes JM, Komm B et al (2003) Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinol 144:4562-4574 (Pubitemid 37204856)
18. Deroo BJ, Korach KS (2006) Estrogen receptors and human disease. J Clin Invest 116:561-570 (Pubitemid 43326860)
19. Norris JD, Fan D, Kerner SA et al (1997) Identification of a third autonomous activation domain within the human estrogen receptor. Mol Endocrinol 11:747-754 (Pubitemid 27225302)
20. Nicholson RI, Hutcheson IR, Knowlden JM et al (2004) Nonendocrine pathways and endocrine resistance observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 10:346s-354s (Pubitemid 38116641)
21. Arpino G, Green SJ, Allred DC et al (2004) HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer a southwest oncology group study. Clin Cancer Res 10:5670-5676 (Pubitemid 39180941)
22. Tang X (2013) Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett
23. Volodko N, Reiner A, Rudas M et al (1998) Tumour-associated macrophages in breast cancer and their prognostic correlations. Breast 7:99-105 (Pubitemid 28230834)
24. Mahmoud SMA, Lee AHS, Paish EC et al (2012) Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol 65: 159-163
25. Morris PG, Hudis CA, Giri D et al (2011) Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) 4:1021-1029
26. Monteiro R, Azevedo I (2010) Chronic inflammation in obesity and the metabolic syndrome. Mediat Inflamm. doi:10.1155/2010/289645
27. Cinti S, Mitchell G, Barbatelli G et al (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46:2347-2355 (Pubitemid 41532523)
28. Zhao Y, Agarwal VR, Mendelson CR et al (1996) Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137:5739-5742 (Pubitemid 26423150)
29. Irahara N, Miyoshi Y, Taguchi T et al (2006) Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer. Int J Cancer 118: 1915-1921
30. Bachelot T, Ray-Coquard I, Menetrier-Caux C et al (2003) Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 88:1721-1726 (Pubitemid 36760416)
31. Dandona P, Weinstock R, Thusu K et al (1998) Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83:2907-2910 (Pubitemid 28493796)
32. Leek RD, Hunt NC, Landers RJ et al (2000) Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol 190:430-436 (Pubitemid 30163582)
33. Yang J, Liao D, Chen C et al (2013) Tumor associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem Cells 31:248-258
34. Vlaicu P, Mertins P, Thomas M et al (2013) Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator. BMC Cancer 13:197
35. Condeelis J, Segall JE (2003) Intravital imaging of cell movement in tumours. Nat Rev Cancer 3:921-930 (Pubitemid 37500177)